Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 55 peer-reviewed journal articles Updated
Pulmonology

Idiopathic Chronic Eosinophilic Pneumonia (ICEP): A Patient Guide

At a Glance

Idiopathic chronic eosinophilic pneumonia is a rare inflammatory lung disease that often improves quickly with prednisone or another systemic steroid, but relapse is common. Ruling out similar conditions, tapering slowly, and monitoring lung health support long-term care.

Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare inflammatory lung condition characterized by the abnormal accumulation of eosinophils, a type of white blood cell, within the air sacs and tissues of the lungs. While these cells normally help the body fight off certain infections, in ICEP, they are recruited to the lungs in excessive numbers by specific immune signals—most notably a protein called IL-5 [1]. Once there, these cells release inflammatory substances that cause inflammation, leading to symptoms that typically develop gradually over several weeks, including a persistent cough, progressive shortness of breath, night sweats, and fatigue [2][3].

Because the symptoms and imaging patterns of ICEP can look like many other conditions, it is fundamentally a diagnosis of exclusion. This means your care team must systematically rule out “mimics,” such as reactions to new medications, parasitic or fungal infections, and more rapid conditions like Acute Eosinophilic Pneumonia (AEP) [4][5]. Furthermore, because many people with ICEP also have asthma, it is crucial to distinguish between a standard asthma flare and this deeper lung inflammation, which may also be a component of systemic disorders like Eosinophilic Granulomatosis with Polyangiitis (EGPA) [6][7].

The cornerstone of treatment is systemic corticosteroids (such as prednisone), which typically produce a rapid and often dramatic improvement in both symptoms and lung imaging [2][8]. However, the hallmark of ICEP is its tendency to return; between 30% and 60% of patients experience a relapse as they try to lower their medication dose or after stopping it entirely [9][10]. This high frequency of recurrence means that management is often a long-term process, requiring a very slow reduction in medication under careful clinician supervision and close monitoring of both blood eosinophil levels and lung function [11][12].

Living with ICEP requires a focus on long-term health, as prolonged treatment can lead to side effects like bone thinning, blood sugar changes, or increased infection risk, and the disease itself can sometimes leave residual scarring on the lungs [13][1]. Finding a pulmonologist who is familiar with rare lung diseases is vital for navigating these complexities [14]. By working with a specialist who understands the nuances of this rare condition, you can ensure that your treatment is precisely balanced to keep the inflammation at bay while protecting your overall well-being [15][16].

In this guide

5 chapters

01

Understanding Your Diagnosis: ICEP

Learn how idiopathic chronic eosinophilic pneumonia (ICEP) is diagnosed, including symptoms, blood and lung-fluid tests, CT findings, and urgent warning signs

02

Biology, Mimics & The Diagnostic Process

Learn how idiopathic chronic eosinophilic pneumonia (ICEP) is diagnosed, including blood and BAL eosinophils, CT patterns, and tests that rule out mimics.

03

Standard of Care Treatment

Learn how idiopathic chronic eosinophilic pneumonia is treated with steroids, safe tapering, relapse monitoring, and biologic options for frequent relapses.

04

Monitoring, Relapse, and Long-Term Health with ICEP

Learn how to monitor idiopathic chronic eosinophilic pneumonia for relapse, track lung function, and manage long-term steroid side effects and health risks.

05

Building Your Care Team

Learn how to build a care team for idiopathic chronic eosinophilic pneumonia, choose specialists, organize files, and plan monitoring for steroids and relapses.

Common questions in this guide

What is idiopathic chronic eosinophilic pneumonia?
ICEP is a rare inflammatory lung condition in which too many eosinophils, a type of white blood cell, collect in lung tissue and air sacs. The inflammation can cause symptoms that build over several weeks, including cough, shortness of breath, night sweats, and fatigue.
How do doctors diagnose ICEP?
ICEP is a diagnosis of exclusion, so doctors first consider and rule out conditions that can look similar. These may include medication reactions, parasitic or fungal infections, acute eosinophilic pneumonia, asthma-related problems, and EGPA. Symptoms, lung imaging, blood eosinophil levels, and clinical history help guide the evaluation.
What is the usual treatment for ICEP?
Systemic corticosteroids, such as prednisone, are the main treatment for ICEP. Symptoms and lung imaging often improve quickly, but the medication generally needs to be reduced slowly under clinician supervision rather than stopped abruptly.
How likely is ICEP to come back after treatment?
Relapse occurs in about 30% to 60% of people with ICEP, often while the steroid dose is being lowered or after treatment stops. A slow taper and follow-up monitoring of blood eosinophils, symptoms, and lung function can help clinicians identify recurrence.
How can I tell an ICEP relapse from an asthma flare?
Cough and shortness of breath can occur with both conditions, so symptoms alone may not be enough to tell them apart. A pulmonologist may consider the timing of symptoms, blood eosinophil levels, lung function, and imaging when assessing whether ICEP inflammation has returned. Do not change your steroid dose without medical guidance.
What long-term side effects should be monitored during steroid treatment?
Long-term systemic steroids can contribute to bone thinning, blood sugar changes, and increased infection risk. Ask your care team how they will monitor bone density and blood sugar and how they will reduce treatment risks while controlling ICEP.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How did you ensure that my symptoms aren't caused by a 'mimic' like a medication reaction, a parasite, or a more systemic condition like EGPA?
  2. 2.Do you have experience managing rare eosinophilic lung diseases, and do you collaborate with radiologists or pathologists when cases are complex?
  3. 3.Given the high rate of relapse in ICEP, what is your specific strategy for monitoring me during the steroid tapering process?
  4. 4.What symptoms should I specifically look for that distinguish an asthma flare from an ICEP relapse?
  5. 5.What is our long-term plan to monitor for side effects of steroid treatment, such as bone density or blood sugar changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies.

    Scelfo C, Simonazzi A, Ruggiero P, et al.

    Frontiers in immunology 2026; (17()):1893402 doi:10.3389/fimmu.2026.1893402.

    PMID: 42666554
  2. 2

    Chronic eosinophilic pneumonia: Adjunctive therapy with inhaled steroids.

    Chan C, DeLapp D, Nystrom P

    Respiratory medicine case reports 2017; (22()):11-14 doi:10.1016/j.rmcr.2017.05.014.

    PMID: 28626631
  3. 3

    Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study.

    Xu Y, Wang Z, Li W, et al.

    The clinical respiratory journal 2022; (16(1)):35-42 doi:10.1111/crj.13448.

    PMID: 34610651
  4. 4

    Eosinophilic Lung Diseases.

    Cottin V

    Clinics in chest medicine 2025; (46(4)):667-684 doi:10.1016/j.ccm.2025.07.007.

    PMID: 41110928
  5. 5

    Eosinophilic Pneumonias.

    Allen J, Wert M

    The journal of allergy and clinical immunology. In practice 2018; (6(5)):1455-1461 doi:10.1016/j.jaip.2018.03.011.

    PMID: 29735405
  6. 6

    Eosinophilic Lung Diseases.

    Cottin V

    Immunology and allergy clinics of North America 2023; (43(2)):289-322 doi:10.1016/j.iac.2023.01.002.

    PMID: 37055090
  7. 7

    Predictive factors for relapse in corticosteroid-treated patients with chronic eosinophilic pneumonia.

    Takeuchi N, Arai T, Sasaki Y, et al.

    Journal of thoracic disease 2022; (14(11)):4352-4360 doi:10.21037/jtd-22-511.

    PMID: 36524087
  8. 8

    The Long-term Clinical Course of Chronic Eosinophilic Pneumonia.

    Ishiguro T, Takayanagi N, Uozumi R, et al.

    Internal medicine (Tokyo, Japan) 2016; (55(17)):2373-7 doi:10.2169/internalmedicine.55.6765.

    PMID: 27580536
  9. 9

    Persistent impairment on spirometry in chronic eosinophilic pneumonia: A longitudinal observation study (Shizuoka-CEP study).

    Suzuki Y, Oyama Y, Hozumi H, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2017; (119(5)):422-428.e2 doi:10.1016/j.anai.2017.08.009.

    PMID: 28942952
  10. 10

    Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia.

    Oyama Y, Fujisawa T, Hashimoto D, et al.

    The European respiratory journal 2015; (45(6)):1624-31 doi:10.1183/09031936.00199614.

    PMID: 25614171
  11. 11

    Optimal dose of maintenance steroid therapy for relapse of chronic eosinophilic pneumonia: a multicentre retrospective study.

    Atsumi K, Nishima S, Tanaka T, et al.

    BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2024-002697.

    PMID: 40379264
  12. 12

    Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

    Tashiro H, Takahashi K, Kurihara Y, et al.

    Journal of asthma and allergy 2022; (15()):169-177 doi:10.2147/JAA.S343272.

    PMID: 35177908
  13. 13

    Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis.

    Baqir M, Peikert T, Johnson TF, et al.

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2022; (39(2)):e2022020 doi:10.36141/svdld.v39i2.12656.

    PMID: 36118537
  14. 14

    Survey of physicians' approaches to the clinical evaluation of interstitial lung disease in Singapore (SoPhoCLES).

    Teo FSW, Chai GT, Low SY, et al.

    Journal of thoracic disease 2025; (17(11)):9439-9450 doi:10.21037/jtd-2025-1365.

    PMID: 41377003
  15. 15

    Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

    Wells A, Devaraj A, Renzoni EA, Denton CP

    Seminars in respiratory and critical care medicine 2019; (40(2)):184-193 doi:10.1055/s-0039-1684020.

    PMID: 31137059
  16. 16

    The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

    Richeldi L, Launders N, Martinez F, et al.

    ERJ open research 2019; (5(2)) doi:10.1183/23120541.00209-2018.

    PMID: 30949489

This page provides information about ICEP diagnosis, treatment, relapse, and steroid monitoring for educational purposes only and does not constitute medical advice. Discuss your symptoms and any steroid taper with your pulmonologist or another healthcare professional.

Get notified when new evidence is published on Idiopathic chronic eosinophilic pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.